NEW YORK, March 9 /PRNewswire-Asia-FirstCall/ -- NeoStem, Inc. (“NeoStem” or the “Company”), an international biopharmaceutical company with operations in the U.S. and China, announced today that the Company will present at the upcoming ROTH Capital Partners 22nd Annual OC Growth Stock Conference to be held on March 15-17, 2010.
Robin Smith, M.D., NeoStem’s CEO and Chairman of the board of directors, will be available for one-on-one meetings with institutional investors on March 15 at the conference.
About NeoStem, Inc.
NeoStem, Inc. is engaged in the development of stem cell-based therapies, pursuit of anti-aging initiatives and building of a network of adult stem cell collection centers in the U.S. and China that are focused on enabling people to donate and store their own (autologous) stem cells for their personal use in times of future medical need. The Company also has licensed various stem cell technologies, including a worldwide exclusive license to VSEL(TM) technology which uses very small embryonic-like stem cells, shown to have several physical characteristics that are generally found in embryonic stem cells, and is pursuing the licensing of other technologies for therapeutic use. NeoStem’s majority-controlled Chinese pharmaceutical operation, Suzhou Erye, manufactures and distributes generic antibiotics in China. For more information, please visit: http://www.neostem.com .
CONTACT: Robin Smith, CEO of NeoStem, Inc., +1-212-584-4174, or
rsmith@neostem.com; or at CCG Investor Relations, Inc., Lei Huang, Account
Manager, +1-646-833-3417, or lei.huang@ccgir.com, or Crocker Coulson,
President, +1-646-213-1915, or crocker.coulson@ccgir.com, for NeoStem
Web site: http://www.neostem.com//
